GlassScriptPhysician profile
Thomas Whealton
NPI 1811254105
$5,585.81
in general payments reported to CMS, 2019-2025
25 companies · $1,054 in 2025
The $1,054 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,022 · 2020: $458 · 2021: $685 · 2022: $373 · 2023: $1,061 · 2024: $934 · 2025: $1,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,465 · Travel and Lodging: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,464.82 |
| Travel and Lodging | $583.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,587.97 | 2019-2024 | Senza |
| Globus Medical, INC. | $985.63 | 2025 | Senza, Vyrsa V1 |
| Medtronic, INC. | $582.93 | 2021-2023 | Kyphon Express II Kyphopak Tray |
| Boston Scientific Corporation | $427.68 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Medtronic USA, INC. | $298.11 | 2019 | |
| Averitas Pharma INC. | $152.97 | 2024 | Qutenza |
| Pacira Therapeutics, INC. | $80.12 | 2019-2020 | |
| Amgen INC. | $75.86 | 2019-2020 | |
| Abbott Laboratories | $71.25 | 2019-2022 | |
| Si-Bone, INC. | $62.51 | 2019-2021 | |
| Daiichi Sankyo INC. | $30.16 | 2019 | |
| Collegium Pharmaceutical, INC. | $25.17 | 2019 | |
| Fidia Pharma USA INC. | $23.11 | 2025 | Hymovis, Triluron |
| Nalu Medical, INC. | $21.59 | 2024 | Nalu Neurostimulation System |
| Painteq LLC | $19.82 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.64 | 2022 | |
| Curonix LLC | $15.90 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| International Rehabilitative Sciences, INC | $15.38 | 2025 | Rs-4i Plus With Intersperse |
| Lilly USA, LLC | $14.78 | 2019 | |
| Allergan, INC. | $14.67 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.09 | 2019 | |
| Valinor Pharma, LLC | $13.97 | 2025 | Movantik |
| Bioventus LLC | $12.57 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.89 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Whealton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.